Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE)
NCT05465343
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
24
Enrollment
OTHER
Sponsor class
Conditions
Furmonertinib
EGFR-mutation
NSCLC
Brain Metastases
Interventions
DRUG:
Furmonertinib 160 mg, Q.D.
Sponsor
Peking Union Medical College